Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7821357 | 0.99 | MARS1 (0.98) | MARS1 | |
| SCHEMBL7821091 | 0.98 | MARS1 (0.96) | MARS1 | |
| SCHEMBL7806974 | 0.97 | MARS1 (0.94) | MARS1 | |
| SCHEMBL7815628 | 0.93 | MARS1 (0.87) | MARS1 | |
| SCHEMBL7817766 | 0.90 | MARS1 (0.82) | MARS1 | |
| SCHEMBL7821298 | 0.90 | MARS1 (0.82) | MARS1 | |
| SCHEMBL5668780 | 0.87 | MARS1 (0.77) | MARS1 | |
| SCHEMBL7818272 | 0.87 | MARS1 (0.76) | MARS1 | |
| SCHEMBL5669849 | 0.86 | MARS1 (0.76) | MARS1 | |
| SCHEMBL7814907 | 0.86 | MARS1 (0.76) | MARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1351688-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | claimed |
| US-20040039017-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | claimed |
| EP-1351688-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | claimed |
| WO-2002047687-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-20 | — | — | WO | claimed |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| US-20040039017-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | disclosed |
| US-6320051-B1 | AMINO(NH) OR OXYGEN(O) SUBSTITUTED, ENZYME INHIBITORS OF STAPHLOCCOCUS AUREUS METHIONYL T-RNA SYNTHETASE (MRS); ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2001-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | MARS1 55/4885 |
| US-20040039017-A1 | Urotensin-II receptor antagonists | UTS2R, NTSR2, PLAUR | MARS1 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.